X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AUROBINDO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AUROBINDO PHARMA ASTRAZENECA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 416.2 19.4 2,143.3% View Chart
P/BV x 20.4 3.6 559.3% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
AUROBINDO PHARMA
Mar-18
ASTRAZENECA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285809 158.8%   
Low Rs634504 125.8%   
Sales per share (Unadj.) Rs189.6281.1 67.5%  
Earnings per share (Unadj.) Rs-0.241.4 -0.5%  
Cash flow per share (Unadj.) Rs3.850.9 7.6%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.6199.4 34.4%  
Shares outstanding (eoy) m25.00585.88 4.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.3 216.7%   
Avg P/E ratio x-4,712.715.9 -29,686.6%  
P/CF ratio (eoy) x249.612.9 1,934.3%  
Price / Book Value ratio x14.03.3 424.5%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m23,988384,630 6.2%   
No. of employees `0001.617.3 9.0%   
Total wages/salary Rs m1,60521,308 7.5%   
Avg. sales/employee Rs Th3,040.29,500.7 32.0%   
Avg. wages/employee Rs Th1,029.21,229.4 83.7%   
Avg. net profit/employee Rs Th-3.31,397.9 -0.2%   
INCOME DATA
Net Sales Rs m4,740164,666 2.9%  
Other income Rs m921,020 9.0%   
Total revenues Rs m4,832165,686 2.9%   
Gross profit Rs m-13037,718 -0.3%  
Depreciation Rs m1015,580 1.8%   
Interest Rs m0777 0.0%   
Profit before tax Rs m-13932,380 -0.4%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m58,183 0.1%   
Profit after tax Rs m-524,229 -0.0%  
Gross profit margin %-2.722.9 -12.0%  
Effective tax rate %-3.725.3 -14.5%   
Net profit margin %-0.114.7 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,726121,878 2.2%   
Current liabilities Rs m2,43586,806 2.8%   
Net working cap to sales %6.121.3 28.9%  
Current ratio x1.11.4 79.7%  
Inventory Days Days74130 56.8%  
Debtors Days Days4168 59.6%  
Net fixed assets Rs m1,03581,037 1.3%   
Share capital Rs m50586 8.5%   
"Free" reserves Rs m942116,218 0.8%   
Net worth Rs m1,716116,804 1.5%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m4,156211,052 2.0%  
Interest coverage xNM42.7-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.8 146.2%   
Return on assets %-0.111.8 -1.0%  
Return on equity %-0.320.7 -1.4%  
Return on capital %027.4 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37580,727 0.5%   
Fx outflow Rs m47034,700 1.4%   
Net fx Rs m-9646,027 -0.2%   
CASH FLOW
From Operations Rs m-819,548 -0.0%  
From Investments Rs m-146-19,570 0.7%  
From Financial Activity Rs m8628,642 10.0%  
Net Cashflow Rs m7098,922 7.9%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 15.7 27.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   12,856 69,601 18.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS